Report

src

Global Covid-19 Clinical Trials Market by Types (Therapeutics, Drugs) and by End-Users/Application (Phase I, Phase II, Phase III, Phase IV) Global Market Share, Forecast Data, In-Depth Analysis, and Detailed Overview, and Forecast, 2015 - 2027

 Report Code
 Category
 Published Date
 Pages
 Format
MNR-1404
Medical Devices
05 October 2020
207
PDF
Customization
  • We provide customized solutions to cater to your specific requirement services any region, product, or any specific market segment.

The report on the global Covid-19 clinical trials market analyzes complete scenario i.e., existing as well as future visions of Covid-19 clinical trials market. It includes detailed overview of Covid-19 clinical trials market along with market pictures. Additionally, report has included complete data of the various segments in the global Covid-19 clinical trials market followed by its phases, end users and region wide segmentation. Moreover, report has highlights of global key players present in this market. Top global players are analyzed completely along with their financials, technological innovations, key developments, apart from future strategies, SWOT analysis, acquisitions & mergers, and market footprint.

Global Covid-19 clinical trials market report offers in-depth insights, revenue details, and other vital information regarding the global Covid-19 clinical trials market, and the various trends, drivers, restraints, opportunities, and threats in the target market till year 2026. Hence, it covers the impact of these drivers and restraints on demand for this market during the forecast period. The report also includes PEST analysis, Porter’s Five Forces analysis, and opportunity map analysis for in-depth understanding of the market.

It provides historical data along with future forecast as well as detailed analysis of market on a global, regional and country level. Important market data of this market is projected in the form of form of tables, graphics, and pictures. On a regional basis, the market is categorized into five regions that include North America, Europe, Asia Pacific, Latin America, and Middle & East Africa. It analyzes complete scenario of each and every region along with highest share holder of Covid-19 clinical trials market.

Market Segmentation:
Segmentation by Type Therapeutics
Drugs
Segmentation by Application Phase I
Phase II
Phase III
Phase IV
Market, By Regions North America (the United States, Canada, and Mexico)
Europe (Germany, UK, France, Italy, and Russia, etc.)
Asia-Pacific (China, Japan, ASEAN, India, and Korea)
The Middle East and Africa (UAE, Egypt, South Africa, Saudi Arabia)
South America (Brazil, Chile, Peru, and Argentina)

In addition, Covid-19 clinical trials market report sorted and categorized the information and data according to the major geographical regions which are expected to impact on the industry in forecast period.

Report also provides factors that are contributing to and influencing the expansion of the global Covid-19 clinical trials market. It projects the market assessment for the predicted time. Along with all these report includes the manufacturing process along with shipment, price, revenue, gross profit, potential, interview records, business distribution, etc. This enables users to get complete scenario of competitive analysis of the market.

Pivotal Fundamentals of the Global Covid-19 Clinical Trials Market Report:
  • Holistic in-depth detailed analysis, regarding the parent market.
  • Detailed information about the current R&D activities performed by each Covid-19 clinical trials market player.
  • Region-wise and country-wise breakdown of the Covid-19 clinical trials market to get the revenue, and growth lookout in these areas.
  • Key factors which are influencing the consumption pattern of consumers across various regions and countries.
  • Historical and future progress of the global Covid-19 clinical trials market.
  • Year-on-year growth of the global Covid-19 clinical trials market in terms of value and volume.
Conclusion:
At last report covers a short outline of the dealers, distributors, and suppliers. Additionally, it provides sales channel, analysis findings and results. It spots some new entrants within the market. The study thus, suggests a brand new proposition to embellish Covid-19 clinical trials market and nurture business as it explains current global market as well as future market.

Chapter 1 Covid-19 Clinical Trials Overview
1.1 Product Overview and Scope of Covid-19 Clinical Trials

Chapter 2 Impact of COVID 19
2.1 Impact on Healthcare Industry
2.2 Impact on Covid-19 Clinical Trials
2.3 Consumer Buying Behavior based on Covid-19 Clinical Trials
2.4 Recovery and forecast Analysis based on Covid-19 Clinical Trials

Chapter 3 Executive Summary 
3.1 Drivers for Covid-19 Clinical Trials: 
3.2 Restrain for Covid-19 Clinical Trials:
3.3 Opportunity for Covid-19 Clinical Trials: 
3.4 Global Covid-19 Clinical Trials, 2015 - 2027
3.5 Global Covid-19 Clinical Trials, by Region, 2015 - 2027
3.6 Global Covid-19 Clinical Trials, by Type, 2015 - 2027
3.7 Global Covid-19 Clinical Trials, by Phase, 2015 - 2027

Chapter 4 Covid-19 Clinical Trials Segment by Types (Product Category) 
4.1 Global Covid-19 Clinical Trials Revenue (USD Million) and Growth Rate (%) Comparison by Types  (2015-2020) 
4.2 Global Covid-19 Clinical Trials Revenue Market Share (%) by Types in 2019
4.3 Therapeutics
4.4 Drugs

Chapter 5 Global Covid-19 Clinical Trials Segment by Phase 
5.1 Global Covid-19 Clinical Trials Revenue (USD Million) Comparison by Phase (2015-2027) 
5.2 Phase I
5.3 Phase II
5.4 Phase III
5.5 Phase IV

Chapter 6 Global Covid-19 Clinical Trials by Regions (2015-2027) 
6.1 Global Covid-19 Clinical Trials Size and Growth Rate (%) Comparison by Regions (2015-2027) 
6.2 North America Covid-19 Clinical Trials Status and Prospect (2015-2027) 
6.3 Europe Covid-19 Clinical Trials Status and Prospect (2015-2027) 
6.4 Asia Pacific Covid-19 Clinical Trials Status and Prospect (2015-2027) 
6.5 South America Covid-19 Clinical Trials Status and Prospect (2015-2027) 
6.6 Middle East & Africa Covid-19 Clinical Trials Status and Prospect (2015-2027) 
6.7 Global Covid-19 Clinical Trials Size (2015-2027) 
            6.7.1 Global Covid-19 Clinical Trials Revenue Status and Outlook (2015-2027) 
            
Chapter 7 PESTEL Analysis
7.1 Political Factors
7.2 Economic Factors
7.3 Social Factors
7.4 Technological Factors
7.5 Legal Factors
7.6 Environment Factors

Chapter 8 Global Covid-19 Clinical Trials Competition by Manufacturers
8.1 Global Covid-19 Clinical Trials Revenue and Share by Manufacturers (2015-2019) 

Chapter 9 Company (Top Players) Profiles and Key Data
9.1 Moderna, Inc.
            9.1.1 Company Basic Information and Sales Area
            9.1.2 Business Segment/ Overview
            9.1.3 Investment in Research and Development
            9.1.4 Covid-19 Clinical Trials Product Types Specification
            9.1.5 Key Developments
            9.1.6 Business Strategy
9.2 GlaxoSmithKline plc
            9.2.1 Company Basic Information and Sales Area
            9.2.2 Business Segment/ Overview
            9.2.3 Investment in Research and Development
            9.2.4 Covid-19 Clinical Trials Product Types Specification
            9.2.5 Business Strategy
9.3 Pfizer Inc.
            9.3.1 Company Basic Information and Sales Area
            9.3.2 Business Segment/ Overview
            9.3.3 Covid-19 Clinical Trials Product Types Specification
            9.3.4 Key Developments
            9.3.5 Business Strategy
9.4 Johnson & Johnson
            9.4.1 Company Basic Information and Sales Area. 
            9.4.2 Business Segment/ Overview
            9.4.3 Covid-19 Clinical Trials Product Types Specification
            9.4.4 Business Strategy
9.5 Gilead Sciences Inc.
            9.5.1 Company Basic Information and Sales Area. 
            9.5.2 Business Segment/ Overview
            9.5.3 Covid-19 Clinical Trials Product Types Specification
            9.5.4 Business Strategy
9.6 INOVIO Pharmaceuticals
            9.6.1 Company Basic Information and Sales Area
            9.6.2 Business Segment/ Overview
            9.6.3 Covid-19 Clinical Trials Product Types Specification
            9.6.4 Business Strategy
9.7 AbbVie Inc.
            9.7.1 Company Basic Information and Sales Area
            9.7.2 Business Segment/ Overview
            9.7.3 Investment in Research and Development
            9.7.4 Covid-19 Clinical Trials Product Types Specification
            9.7.5 Key Developments
            9.7.6 Business Strategy
9.8 BioNTech SE
            9.8.1 Company Basic Information and Sales Area. 
            9.8.2 Business Segment/ Overview
            9.8.3 Covid-19 Clinical Trials Product Types Specification
            9.8.4 Business Strategy
9.9 Novavax
            9.9.1 Company Basic Information and Sales Area
            9.9.2 Business Segment/ Overview
            9.9.3 Covid-19 Clinical Trials Product Types Specification
            9.9.4 Business Strategy
9.10 Takeda
            9.10.1 Company Basic Information and Sales Area
            9.10.2 Business Segment/ Overview
            9.10.3 Covid-19 Clinical Trials Product Types Specification
            9.10.4 Business Strategy
            
Chapter 10 Global Covid-19 Clinical Trials Revenue by Regions (2015-2020) 
10.1 Global Covid-19 Clinical Trials Revenue and Market Share (%) by Regions (2015-2020) 

Chapter 11 Global Covid-19 Clinical Trials Revenue by Types
11.1 Global Covid-19 Clinical Trials Revenue and Market Share (%) by Types (2015-2020) 

Chapter 12 Global Covid-19 Clinical Trials Analysis by Phase
12.1 Global Covid-19 Clinical Trials Revenue (USD Million) and Market Share (%) by Phase (2015-2020) 
12.2 Global Covid-19 Clinical Trials Revenue Growth Rate by Phase (2015-2020) 

Chapter 13 North America Covid-19 Clinical Trials Development Status and Outlook
13.1 North America Covid-19 Clinical Trials Size (2015-2020) 
            13.1.1 North America Covid-19 Clinical Trials Size by Type (USD Million) (2015-2020) 
13.2 North America Covid-19 Clinical Trials Size (2015-2020) 
            13.2.1 North America COVID-19 CLINICAL TRIALS Size by Phase (USD Million) (2015-2020) 
13.3 U.S
            13.3.1 U.S. Covid-19 Clinical Trials, by Type, 2015 - 2027
            13.3.2 U.S. Covid-19 Clinical Trials, by Phase, 2015 – 2027
13.4 Canada
            13.4.1 Canada Covid-19 Clinical Trials, by Type, 2015 - 2027
            13.4.2 Canada Covid-19 Clinical Trials, by Phase, 2015 – 2027
13.5 Mexico
            13.5.1 Mexico Covid-19 Clinical Trials, by Type, 2015 - 2027
            13.5.2 Mexico Covid-19 Clinical Trials, by Phase, 2015 – 2027
            
Chapter 14 Europe Covid-19 Clinical Trials Development Status and Outlook
14.1 Europe Covid-19 Clinical Trials Size (2015-2020) 
            14.1.1 Europe Covid-19 Clinical Trials Size by Type (USD Million) (2015-2020) 
14.2 Europe Covid-19 Clinical Trials Size (2015-2020) 
            14.2.1 Europe Covid-19 Clinical Trials Size by Phase (USD Million) (2015-2020) 
14.3 U.K.
            14.3.1 U.K. Covid-19 Clinical Trials, by Type, 2015 - 2027
            14.3.2 U.K. Covid-19 Clinical Trials, by Phase, 2015 – 2027
14.4 Germany
            14.4.1 Germany Covid-19 Clinical Trials, by Type, 2015 - 2027
            14.4.2 Germany Covid-19 Clinical Trials, by Phase, 2015 – 2027
14.5 France
            14.5.1 France Covid-19 Clinical Trials, by Type, 2015 – 2027
            14.5.2 France Covid-19 Clinical Trials, by Phase, 2015 – 2027
14.6 Italy
            14.6.1 Italy Covid-19 Clinical Trials, by Type, 2015 – 2027
            14.6.2 Italy Covid-19 Clinical Trials, by Phase, 2015 – 2027
14.7 Spain
            14.7.1 Spain Covid-19 Clinical Trials, by Type, 2015 – 2027
            14.7.2 Spain Covid-19 Clinical Trials, by Phase, 2015 – 2027
14.8 Rest of Europe
            14.8.1 Rest of Europe Covid-19 Clinical Trials, by Type, 2015 – 2027
            14.8.2 Rest of Europe Covid-19 Clinical Trials, by Phase, 2015 – 2027
            
Chapter 15 Asia Pacific Covid-19 Clinical Trials Development Status and Outlook
15.1 Asia Pacific Covid-19 Clinical Trials Size (2015-2020) 
            15.1.1 Asia Pacific Covid-19 Clinical Trials Size by Type (USD Million) (2015-2020) 
15.2 Asia Pacific Covid-19 Clinical Trials Size (2015-2020) 
            15.2.1 Asia Pacific COVID-19 CLINICAL TRIALS Size by Phase (USD Million) (2015-2020) 
15.3 China
            15.3.1 China Covid-19 Clinical Trials, by Type, 2015 – 2027
            15.3.2 China Covid-19 Clinical Trials, by Phase, 2015 – 2027
15.4 Japan
            15.4.1 Japan Covid-19 Clinical Trials, by Type, 2015 – 2027
            15.4.2 Japan Covid-19 Clinical Trials, by Phase, 2015 – 2027
15.5 India
            15.5.1 India Covid-19 Clinical Trials, by Type, 2015 – 2027
            15.5.2 India Covid-19 Clinical Trials, by Phase, 2015 – 2027
15.6 Southeast Asia
            15.6.1 Southeast Asia Covid-19 Clinical Trials, by Type, 2015 – 2027
            15.6.2 Southeast Asia Covid-19 Clinical Trials, by Phase, 2015 – 2027
            
Chapter 16 South America Covid-19 Clinical Trials Development Status and Outlook
16.1 South America Covid-19 Clinical Trials Size (2015-2020) 
            16.1.1 South America Covid-19 Clinical Trials Size by Type (USD Million) (2015-2020) 
16.2 South America Covid-19 Clinical Trials Size (2015-2020) 
            16.2.1 South America Covid-19 Clinical Trials Size by Phase (USD Million) (2015-2020) 
16.3 Brazil
            16.3.1 Brazil Covid-19 Clinical Trials, by Type, 2015 – 2027
            16.3.2 Brazil Covid-19 Clinical Trials, by Phase, 2015 – 2027 
16.4 Argentina
            16.4.1 Argentina Covid-19 Clinical Trials, by Type, 2015 – 2027
            16.4.2 Argentina Covid-19 Clinical Trials, by Phase, 2015 – 2027 
16.5 Colombia
            16.5.1 Colombia Covid-19 Clinical Trials, by Type, 2015 – 2027
            16.5.2 Colombia Covid-19 Clinical Trials, by Phase, 2015 – 2027
16.6 Rest of South America
            16.6.1 Colombia Covid-19 Clinical Trials, by Type, 2015 – 2027
            16.6.2 Colombia Covid-19 Clinical Trials, by Phase, 2015 – 2027
            
Chapter 17 Middle East & Africa Covid-19 Clinical Trials Development Status and Outlook
17.1 Middle East & Africa Covid-19 Clinical Trials Size (2015-2020) 
            17.1.1 Middle East & Africa Covid-19 Clinical Trials Size by Type (USD Million) (2015-2020) 
17.2 Middle East & Africa Covid-19 Clinical Trials Size (2015-2020) 
            17.2.1 Middle East & Africa Covid-19 Clinical Trials Size by Phase (2015-2020) 
17.3 UAE
            17.3.1 UAE Covid-19 Clinical Trials, by Type, 2015 – 2027
            17.3.2 UAE Covid-19 Clinical Trials, by Phase, 2015 – 2027
17.4 South Africa
            17.4.1 South Africa Covid-19 Clinical Trials, by Type, 2015 – 2027
            17.4.2 South Africa Covid-19 Clinical Trials, by Phase, 2015 – 2027
17.5 Egypt
            17.5.1 Egypt Covid-19 Clinical Trials, by Type, 2015 – 2027
            17.5.2 Egypt Covid-19 Clinical Trials, by Phase, 2015 – 2027
17.6 Rest of MEA
            17.6.1 Rest of MEA Covid-19 Clinical Trials, by Type, 2015 – 2027
            17.6.2 Rest of MEA Covid-19 Clinical Trials, by Phase, 2015 – 2027
            
Chapter 18 Covid-19 Clinical Trials Manufacturing Cost Analysis
18.1 Proportion of Manufacturing Cost Structure
            18.1.1 Raw Materials
            18.1.2 Labor Cost
            18.1.3 USA Labor Cost Analysis
            18.1.4 EU Labor Costs Analysis
            18.1.5 China Labor Costs Analysis
            18.1.6 Manufacturing Expenses
            
Chapter 19 Marketing Strategy Analysis, Distributors/ Traders
19.1 Marketing Channel
            19.1.1 Direct Marketing
            19.1.2 Indirect Marketing
            19.1.3 Marketing Channel Development Trend
19.2 Market Positioning
            19.2.1 Pricing Strategy
            
Chapter 20 Global Covid-19 Clinical Trials Forecast (2020-2027) 
20.1 Global Covid-19 Clinical Trials Revenue Forecast (2020-2027) 
            20.1.1 Global Covid-19 Clinical Trials Revenue (USD Million) and Growth Rate (%) Forecast (2020-2027) 
20.2 Global Covid-19 Clinical Trials Revenue (USD Million) Forecast by Regions (2020-2027) 
            20.2.1 North America Covid-19 Clinical Trials Revenue (USD Million) Forecast (2020-2027) 
            20.2.2 Europe Covid-19 Clinical Trials Revenue (USD Million) Forecast (2020-2027) 
            20.2.3 Asia Pacific Covid-19 Clinical Trials and Revenue (USD Million) Forecast (2020-2027) 
            20.2.4 South America Covid-19 Clinical Trials and Revenue (USD Million) Forecast (2020-2027) 
            20.2.5 Middle East & Africa Covid-19 Clinical Trials and Revenue (USD Million) Forecast (2020-2027) 
20.3 Global Covid-19 Clinical Trials Revenue Forecast by Type (2020-2027) 
20.4 Global Covid-19 Clinical Trials Revenue (USD Million) Forecast by Phase (2020-2027) 

Chapter 21 North America Covid-19 Clinical Trials Development Status and Outlook
21.1 North America Covid-19 Clinical Trials Size (2020-2027) 
            21.1.1 North America Covid-19 Clinical Trials Size by Type (USD Million) (2020-2027) 
21.2 North America Covid-19 Clinical Trials Size (2020-2027) 
            21.2.1 North America Covid-19 Clinical Trials Size by Phase (USD Million) (2020-2027) 
21.3 U.S.
            21.3.1 U.S. Covid-19 Clinical Trials, by Type, 2020 – 2027
            21.3.2 U.S. Covid-19 Clinical Trials, by Phase, 2020 – 2027
21.4 Canada
            21.4.1 Canada Covid-19 Clinical Trials, by Type, 2020 – 2027
            21.4.2 Canada Covid-19 Clinical Trials, by Phase, 2020 – 2027
21.5 Mexico
            21.5.1 Mexico Covid-19 Clinical Trials, by Type, 2020 – 2027
            21.5.2 Mexico Covid-19 Clinical Trials, by Phase, 2020 – 2027
            
Chapter 22 Europe Covid-19 Clinical Trials Development Status and Outlook
22.1 Europe Covid-19 Clinical Trials Size (2020-2027) 
            22.1.1 Europe Covid-19 Clinical Trials Size by Type (USD Million) (2020-2027) 
22.2 Europe Covid-19 Clinical Trials Size (2020-2027) 
            22.2.1 Europe Covid-19 Clinical Trials Size by Phase (USD Million) (2020-2027) 
22.3 U.K.
            22.3.1 U.K. Covid-19 Clinical Trials, by Type, 2020 – 2027
            22.3.2 U.K. Covid-19 Clinical Trials, by Phase, 2020 – 2027
22.4 Germany
            22.4.1 Germany Covid-19 Clinical Trials, by Type, 2020 – 2027
            22.4.2 Germany Covid-19 Clinical Trials, by Phase, 2020 – 2027
22.5 France
            22.5.1 France Covid-19 Clinical Trials, by Type, 2020 – 2027
            22.5.2 France Covid-19 Clinical Trials, by Phase, 2020 – 2027
22.6 Italy
            22.6.1 France Covid-19 Clinical Trials, by Type, 2020 – 2027
            22.6.2 France Covid-19 Clinical Trials, by Phase, 2020 – 2027
22.7 Spain
            22.7.1 France Covid-19 Clinical Trials, by Type, 2020 – 2027
            22.7.2 France Covid-19 Clinical Trials, by Phase, 2020 – 2027
22.8 Rest of Europe
            22.8.1 France Covid-19 Clinical Trials, by Type, 2020 – 2027
            22.8.2 France Covid-19 Clinical Trials, by Phase, 2020 – 2027
            
Chapter 23 Asia Pacific Covid-19 Clinical Trials Development Status and Outlook
23.1 Asia Pacific Covid-19 Clinical Trials Size (2020-2027) 
            23.1.1 Asia Pacific Covid-19 Clinical Trials Size by Type (USD Million) (2020-2027) 
23.2 Asia Pacific Covid-19 Clinical Trials Size (2020-2027) 
            23.2.1 Asia Pacific Covid-19 Clinical Trials Size by Phase (USD Million) (2020-2027) 
23.3 China
            23.3.1 China Covid-19 Clinical Trials, by Type, 2020 – 2027
            23.3.2 China Covid-19 Clinical Trials, by Phase, 2020 – 2027
23.4 Japan
            23.4.1 Japan Covid-19 Clinical Trials, by Type, 2020 – 2027
            23.4.2 Japan Covid-19 Clinical Trials, by Phase, 2020 – 2027
23.5 India
            23.5.1 India Covid-19 Clinical Trials, by Type, 2020 – 2027
            23.5.2 India Covid-19 Clinical Trials, by Phase, 2020 – 2027
23.6 Southeast Asia
            23.6.1 Southeast Asia Covid-19 Clinical Trials, by Type, 2020 – 2027
            23.6.2 Southeast Asia Covid-19 Clinical Trials, by Phase, 2020 – 2027
            
Chapter 24 South America Covid-19 Clinical Trials Development Status and Outlook
24.1 South America Covid-19 Clinical Trials Size (2020-2027) 
            24.1.1 South America Covid-19 Clinical Trials Size by Type (USD Million) (2020-2027) 
24.2 South America Covid-19 Clinical Trials Size (2020-2027) 
            24.2.1 South America Covid-19 Clinical Trials Size by Phase (USD Million) (2020-2027) 
24.3 Brazil
            24.3.1 Brazil Covid-19 Clinical Trials, by Type, 2020 – 2027
            24.3.2 Brazil Covid-19 Clinical Trials, by Phase, 2020 – 2027 
24.4 Argentina
            24.4.1 Argentina Covid-19 Clinical Trials, by Type, 2020 – 2027
            24.4.2 Argentina Covid-19 Clinical Trials, by Phase, 2020 – 2027 
24.5 Colombia
            24.5.1 Colombia Covid-19 Clinical Trials, by Type, 2020 – 2027
            24.5.2 Colombia Covid-19 Clinical Trials, by Phase, 2020 – 2027
24.6 Rest of South America
            24.6.1 Colombia Covid-19 Clinical Trials, by Type, 2020 – 2027
            24.6.2 Colombia Covid-19 Clinical Trials, by Phase, 2020 – 2027
            
Chapter 25 Middle East & Africa Covid-19 Clinical Trials Development Status and Outlook
25.1 Middle East & Africa Covid-19 Clinical Trials Size (2020-2027) 
            25.1.1 Middle East & Africa Covid-19 Clinical Trials Size by Type (USD Million) (2020-2027) 
25.2 Middle East & Africa Covid-19 Clinical Trials Size (2020-2027) 
            25.2.1 Middle East & Africa Covid-19 Clinical Trials Size by Phase (USD Million) (2020-2027) 
25.3 UAE
            25.3.1 UAE Covid-19 Clinical Trials, by Type, 2020 – 2027
            25.3.2 UAE Covid-19 Clinical Trials, by Phase, 2020 – 2027
25.4 South Africa
            25.4.1 South Africa Covid-19 Clinical Trials, by Type, 2020 – 2027
            25.4.2 South Africa Covid-19 Clinical Trials, by Phase, 2020 – 2027
25.5 Egypt
            25.5.1 Egypt Covid-19 Clinical Trials, by Type, 2020 – 2027
            25.5.2 Egypt Covid-19 Clinical Trials, by Phase, 2020 – 2027
25.6 Rest of MEA
            25.6.1 Rest of MEA Covid-19 Clinical Trials, by Type, 2020 – 2027
            25.6.2 Rest of MEA Covid-19 Clinical Trials, by Phase, 2020 – 2027
            
Chapter 26 Research Findings and Conclusion










 

No Methodology

Global Covid-19 Clinical Trials Market Trends:
The global Covid-19 clinical trials is estimated to be worth USD 5,000 million in 2020 and is projected to reach USD 9,750 million by 2027, at a CAGR of 9.5% from 2020 to 2027.

The WHO declared Covid-19 disease as a pandemic due to the extensive scale of the outbreak and this current pandemic poses a severe health risk to the entire population. Almost all the major research-based pharmaceutical firms, various biotechnology and biopharmaceutical companies, as well as research institutes are engaged in a race to develop an effective treatment and vaccine against COVID-19. Therefore, the government regulation in the U.S. and Europe offers numerous options for procedural assistance to enable effective vaccines and drugs to fight against Covid-19 pandemic.

The rapid spread of coronavirus which leads to the surprising number of deaths globally and hence healthcare organizations are focusing on developing new vaccines and treatments is one of the major factor that is driving the growth of the global Covid-19 clinical trials market. Along with this, increasing demand for developing a suitable treatment and vaccine for Covid-19 is another factor that is also driving the growth of the global Covid-19 clinical trials market.

Thus, increasing globalization of clinical trials, rising demand for CROs to conduct clinical trials and technological evolution are some of the major factors that will drive the growth Covid-19 clinical trials market in the forecast period. Along with this, rise in the initiatives by the governments for fast-tracking clinical trials is another factor that will also drive the growth of the Covid-19 clinical trials market in the forecast period. However, due to rise in the impact of the Covid-19 pandemic, the communities, businesses, and industries are closed globally and hence the people are scared to leave their homes and therefore, running clinical trials has become extremely difficult is one of the major factor that is hampering the growth of the global Covid-19 clinical trials market.

Global Covid-19 Clinical Trials Market, By Type:
On the basis of type, Drugs segment accounted for largest share of total revenue generated, because of the huge investments in the development of vaccines, supportive government efforts are also boosting the drugs market growth and around 157 vaccines are in development from July 2020.

Global Covid-19 Clinical Trials, By Application:
The demand of Global Covid-19 Clinical Trials Market is highest from Phase II segment, because it contributed to 30.3% of the global COVID-19 clinical trials, maximum number of therapeutics and vaccines are developed in Phase II and companies are involved in the development of therapeutics and vaccines.

Global Covid-19 Clinical Trials market, By Region:
Report covers the region wise analysis, global Covid-19 clinical trials can be segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Among all, Europe held the largest share in the market because of the large number of clinical trials initiated within the region, the launch of various clinical trial platforms by the U.K. government and to speedup drug development. North America is also having the maximum share in the Covid-19 clinical trials market followed by the Asia Pacific region.

Major Market Players:
The research study includes profiles of leading companies operating in the global Covid-19 clinical trials market. Key players profiled in the report include: Moderna, Inc., GlaxoSmithKline plc, Pfizer Inc., Johnson & Johnson, Gilead Sciences Inc., INOVIO Pharmaceuticals, AbbVie Inc., BioNTech SE, Novavax and Takeda.

Global Covid-19 Clinical Trials Market Report Scope:
Report Parameters Details of Parameter
Market Size 2015-2027
Based Year 2019
Forecast Period Covered 2020-2027
Units for value USD (Million)
Covered Segments Product Type, Application, Geographic Regions
Product Type Therapeutics, Drugs
Applications Phase I, Phase II, Phase III, Phase IV
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Covered Moderna, Inc., GlaxoSmithKline plc, Pfizer Inc., Johnson & Johnson, Gilead Sciences Inc., INOVIO Pharmaceuticals, AbbVie Inc., BioNTech SE, Novavax and Takeda

The report analyzes all the factors which are impacting on the market and on that basis describes the drivers, restraints, and opportunities for the growth of the global Covid-19 clinical trials market. Similarly, report provides the all the segmentations along with the qualitative analysis.

Global Covid-19 Clinical Trials Market: Product analysis
  • Therapeutics
  • Drugs
Global Covid-19 Clinical Trials Market: Application analysis
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
Market, by regions:
In addition, Covid-19 clinical trials report sorted and categorized the information and data according to the major geographical regions which are expected to impact on the industry in forecast period. Following are the regions we covered in this report:
  • North America (U.S., Canada, Mexico)
  • Europe (U.K., France, Germany, Spain, Italy, Central & Eastern Europe, CIS)
  • Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific)
  • Latin America (Brazil, Rest of L.A.)
  • Middle East and Africa (Turkey, GCC, Rest of Middle East)
 
 
 

Want to customize this report?

This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

We offer $1000 worth of FREE customization at the time of purchase